SCIENTIFIC SCOPE OF THE 2025 ODIN CALL ROUND
ODIN focuses on areas that hold a strong potential for the Danish ecosystem and global health in general. The overall focus is on the early, explorative (i.e. precompetitive) phases of drug discovery and clinical diagnostics in human health. Highly innovative, high-risk projects are encouraged.
CORE SCIENTIFIC SCOPE OF ODIN
- Cardiometabolic and Cardiovascular Diseases: Development of innovative approaches to better understand, prevent, diagnose, and/or treat diseases affecting the heart and blood vessels, as well as cardiometabolic conditions including diabetes, obesity, and their interrelated risk factors.
- Infectious diseases: Advancing research and technologies to address the prevention, diagnosis, and treatment of infectious diseases, including novel approaches to combat antimicrobial resistance.
- Regenerative medicine: Development of cutting-edge therapies and technologies to repair, replace, or regenerate damaged tissues and organs.
CARDIOVASCULAR & -METABOLIC DISEASES
INFECTIOUS DISEASES
REGENERATIVE MEDICINE
EXPANDED SCOPE FOR BROADER HEALTHCARE APPLICATIONS
DISEASE-AGNOSTIC PLATFORM TECHNOLOGIES & RESEARCH TOOLS/METHODS
- Disease-agnostic platform technologies and research tools/methods: Innovative technologies, tools, and methods that enable advancements in drug discovery, drug delivery, and/or clinical diagnostics across a broad range of therapeutic areas. These platforms should provide foundational innovations that can be adapted or applied to multiple disease contexts.
Note: Research within the expanded scope areas of ODIN may extend beyond the core scope, provided it is clearly demonstrated how the technology, tool, or method can eventually be applied to at least one of the core scope areas.
DISEASE-AGNOSTIC PLATFORM TECHNOLOGIES & RESEARCH TOOLS/METHODS
The ODIN Steering Group has the mandate to issue specialized calls within strategic areas of interest in the future – including biosolutions.
All projects, regardless of call focus, must be precompetitive, open and designed to meet ODIN’s selection criteria and aim (see folder on Call Guidelines under "Documents").
ABOUT ODIN
We unite bright minds from industry and academia to jointly create need-driven clinical research projects - and pave the way for innovative new treatments and diagnostics. We fund the best project ideas through competitive funding calls. Although companies cannot receive funding, it is free of charge to join.
The platform is sponsored by the Novo Nordisk Foundation with 180 million DKK from 2024-2029.
CONTACT ODIN
You are welcome to contact us if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.
Although the platform spans five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 120, blg 1521-214.
